@prefix this: . @prefix sub: . @prefix np: . @prefix pav: . @prefix rdf: . @prefix infores: . @prefix xsd: . @prefix umls: . @prefix orcid: . @prefix rdfs: . @prefix biolink: . @prefix prov: . @prefix unii: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { umls:C1299487 a biolink:OrganismTaxon; rdfs:label "patients"; biolink:category biolink:OrganismTaxon . unii:0K47UL67F2 a biolink:ChemicalEntity; rdfs:label "Carvedilol"; biolink:category biolink:ChemicalEntity . a biolink:ChemicalEntity; rdfs:label "thiazide"; biolink:category biolink:ChemicalEntity . a biolink:DiseaseOrPhenotypicFeature; rdfs:label "myocardial infarction"; biolink:category biolink:DiseaseOrPhenotypicFeature . sub:_1 rdf:object ; rdf:predicate biolink:treated_by; rdf:subject ; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_2 rdf:object ; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_3 rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_4 rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_5 rdf:object ; rdf:predicate biolink:treated_by; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . sub:_6 rdf:object ; rdf:predicate biolink:treats; rdf:subject unii:0K47UL67F2; a biolink:Association; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:Association; biolink:publications . } sub:provenance { sub:assertion prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627; prov:wasQuotedFrom " Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40%. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. It is indicated for the management of essential. essential. heart failure." . biolink: pav:version "2.3.0" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB"; npx:hasSignature "U/r65UOfFROfafNoL599E6jgtio6BnZAIOQ1yWdFWz31jXT3rO1XdUkfRnFBq0DJBvvLCK6Kgx3dPyzLSxzt4c9/yLUpeWGwA2P6nHElBdOI3E2TPwHNUPGoPM7kjPyL2Jvb6GbpBIpfxJ1oDg7V3VISyL+TYzo8C4zyPsuOawgFdwpv5GRmVcxQikIyseagaWl8jyXG8m67wo16NoNUUoT4UACC70paz+bzcSlgcVxCe4y5TL+nXAzUCM9T8KvBMe714vlQ8/duaRBOhT2Qy0N6qB5gdFeDOWCqvH3VFUtSqqaEQSrrIFvOCO3Ydiuu8DRsmg69hVheB/qGTG5vUA=="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-3668-2627 . }